Quantitation of norovirus-specific IgG before and after infection in immunocompromised patients.
Capsid protein
Human norovirus
IgG antibody
P domain
Quantitative ELISA
Journal
Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]
ISSN: 1678-4405
Titre abrégé: Braz J Microbiol
Pays: Brazil
ID NLM: 101095924
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
29
05
2019
accepted:
12
10
2019
pubmed:
28
10
2019
medline:
11
11
2020
entrez:
28
10
2019
Statut:
ppublish
Résumé
Noroviruses (NoV) cause the majority of non-bacterial gastroenteritis cases worldwide, with genotype II.4 being the most common. The aim of our study was to quantitate norovirus-specific IgG in immunocompromised patients before and after laboratory-confirmed norovirus infection. A quantitative ELISA was developed by coating ELISA plates with recombinantly expressed P domain of GII.1 capsid protein. After testing mouse sera drawn before and after immunization with GII.1- and GII.4 P domain, sera from GII.1- and GII.4 infected patients were tested. The assay reliably detected preexisting NoV-specific IgG antibodies. Sera drawn after infection showed increased antibody concentrations. Antibodies elicited by GII.1- and GII.4 infections could be detected with coated GII.1 capsid protein. IgG levels remained constant during the first week and then increased in the second week after laboratory diagnosis. The results show that immunocompromised patients elicited IgG responses to NoV infections that could be reliably detected with our quantitative ELISA.
Identifiants
pubmed: 31656022
doi: 10.1007/s42770-019-00176-1
pii: 10.1007/s42770-019-00176-1
pmc: PMC7058766
doi:
Substances chimiques
Antibodies, Viral
0
Capsid Proteins
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
183-187Références
Gastroenterol Clin North Am. 2006 Jun;35(2):275-90, viii
pubmed: 16880066
J Virol. 2010 Feb;84(4):1800-15
pubmed: 20007270
PLoS Med. 2015 Mar 24;12(3):e1001807
pubmed: 25803642
J Infect Dis. 1985 Aug;152(2):274-9
pubmed: 2993432
Nat Med. 2003 May;9(5):548-53
pubmed: 12692541
Clin Vaccine Immunol. 2011 Jul;18(7):1187-90
pubmed: 21593238
J Med Virol. 2005 Nov;77(3):439-46
pubmed: 16173019
J Med Virol. 2007 Aug;79(8):1187-93
pubmed: 17597489
J Virol. 2011 Dec;85(24):13027-37
pubmed: 21994457
MMWR Surveill Summ. 2012 Dec 14;61(9):1-12
pubmed: 23235338
J Infect Dis. 1990 Jan;161(1):18-21
pubmed: 2153184
PLoS One. 2012;7(7):e41625
pubmed: 22844506
J Clin Virol. 2013 Sep;58(1):24-30
pubmed: 23849648
J Infect Dis. 2014 Dec 1;210(11):1755-62
pubmed: 24970849
PLoS One. 2008 Jan 23;3(1):e1485
pubmed: 18213393
Immunology. 2012 Jan;135(1):89-99
pubmed: 22044070
Clin Vaccine Immunol. 2015 Aug;22(8):923-9
pubmed: 26041041
J Gen Virol. 2014 Feb;95(Pt 2):278-291
pubmed: 24243731
J Med Virol. 2011 Mar;83(3):525-31
pubmed: 21264875
J Clin Microbiol. 2015 Feb;53(2):373-81
pubmed: 24989606
J Infect Dis. 2000 May;181 Suppl 2:S331-5
pubmed: 10804146
Mol Cell Probes. 2005 Dec;19(6):385-8
pubmed: 16146684
Mol Immunol. 2015 Oct;67(2 Pt A):171-82
pubmed: 25900877
J Infect Dis. 2015 Aug 1;212(3):397-405
pubmed: 25635121
Infect Immun. 1982 Aug;37(2):463-8
pubmed: 6288563